

10266 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

These are just a few examples of evidence which connote pre-arranged assurances by DoD to a select group of companies that they will receive the contract awards for products.

The impact of these listings in the PDR has a devastating effect on competitive generic equivalent drugs as the 'detailmen' of the select group of companies state the following to physicians they call on:

"Doctor - the U.S. Government only accepts our drug as the quality of the smaller drug firms' so called equivalent is no good; the FSN is the Federal Stock Number for our product. "